Advertisement
Singapore markets closed

  • Straits Times Index

    3,410.81
    -29.07 (-0.85%)
     

  • Nikkei

    40,912.37
    -1.28 (-0.00%)
     

  • Hang Seng

    17,799.61
    -228.67 (-1.27%)
     

  • FTSE 100

    8,203.93
    -37.33 (-0.45%)
     

  • Bitcoin USD

    56,426.89
    -1,762.05 (-3.03%)
     

  • CMC Crypto 200

    1,174.10
    -34.59 (-2.86%)
     

  • S&P 500

    5,567.19
    +30.17 (+0.54%)
     

  • Dow

    39,375.87
    +67.87 (+0.17%)
     

  • Nasdaq

    18,352.76
    +164.46 (+0.90%)
     

  • Gold

    2,397.30
    +27.90 (+1.18%)
     

  • Crude Oil

    83.15
    -0.73 (-0.87%)
     

  • 10-Yr Bond

    4.2720
    -0.0830 (-1.91%)
     

  • FTSE Bursa Malaysia

    1,611.02
    -5.73 (-0.35%)
     

  • Jakarta Composite Index

    7,253.37
    +32.48 (+0.45%)
     

  • PSE Index

    6,492.75
    -14.74 (-0.23%)
     

CORRECTED-UPDATE 1-Sanofi seeing 'unprecedented' demand for RSV therapy

Reuters
Updated ·1-min read

(Corrects Oct 20 story in paragraphs 1, 2, 5 to show the drug was co-developed by Sanofi and AstraZeneca)

Oct 20 (Reuters) - French drugmaker Sanofi said on Friday it was seeing an "unprecedented level" of demand for an antibody therapy it co-developed to prevent respiratory syncytial virus (RSV), a leading cause of hospitalizations in infants.

The therapy, branded Beyfortus and jointly developed by Sanofi and AstraZeneca, was approved in July to prevent RSV in infants and toddlers.

Before the approval of Sanofi's drug, Swedish Orphan Biovitrum's treatment, Synagis, was the only approved preventive therapy in the United States for high-risk infants.

ADVERTISEMENT

Around 1% to 3% of children under 12 months of age in the country are hospitalized each year due to RSV, according to the American Academy of Pediatrics.

Sanofi said it is working with AstraZeneca to identify further solutions to meet surging demand. (Reporting by Mariam Sunny and Khushi Mandowara in Bengaluru; Editing by Devika Syamnath and William Mallard)